His primary scientific interests are in Cancer research, PI3K/AKT/mTOR pathway, Protein kinase B, Signal transduction and MAPK/ERK pathway. His work carried out in the field of Cancer research brings together such families of science as Leukemia, Immunology, Kinase and Cell growth. His PI3K/AKT/mTOR pathway research is multidisciplinary, incorporating perspectives in Carcinogenesis, Cancer, Targeted therapy and Wnt signaling pathway.
His research in Protein kinase B intersects with topics in Cancer stem cell, GSK-3 and PTEN. His Signal transduction study incorporates themes from Autocrine signalling and Phosphorylation. His MAPK/ERK pathway research incorporates themes from Protein phosphatase 2, Mitogen-activated protein kinase, Growth factor receptor and Apoptosis.
James A. McCubrey focuses on Cancer research, PI3K/AKT/mTOR pathway, Protein kinase B, Signal transduction and Cell biology. His studies deal with areas such as Cancer, Targeted therapy, Cell growth, Apoptosis and MAPK/ERK pathway as well as Cancer research. His research on PI3K/AKT/mTOR pathway often connects related topics like Pharmacology.
His Protein kinase B study combines topics in areas such as Jurkat cells and Leukemia. The study incorporates disciplines such as Carcinogenesis, Endocrinology and Kinase, Protein kinase A in addition to Signal transduction. His biological study deals with issues like Cytokine, which deal with fields such as Autocrine signalling.
His scientific interests lie mostly in Cancer research, Cancer, PI3K/AKT/mTOR pathway, Cell biology and Signal transduction. His Cancer research study integrates concerns from other disciplines, such as Pancreatic cancer, Cell growth, Cancer cell, Immunology and Targeted therapy. James A. McCubrey works mostly in the field of Cancer, limiting it down to concerns involving Disease and, occasionally, Pandemic, Severe acute respiratory syndrome coronavirus 2 and microRNA.
His PI3K/AKT/mTOR pathway research incorporates elements of Protein kinase B and MAPK/ERK pathway. His Protein kinase B study combines topics from a wide range of disciplines, such as Tyrosine kinase, Kinase, Drug discovery and Imatinib mesylate. The various areas that James A. McCubrey examines in his Cell biology study include Cell cycle, Cell and Cellular differentiation.
James A. McCubrey mainly investigates Cancer research, PI3K/AKT/mTOR pathway, Cancer, Protein kinase B and Immunology. His biological study spans a wide range of topics, including Cell growth, Tumor microenvironment, Cancer cell, Metastasis and Regulation of gene expression. His PI3K/AKT/mTOR pathway study frequently draws connections between related disciplines such as MAPK/ERK pathway.
Protein kinase B is the subject of his research, which falls under Cell biology. James A. McCubrey is interested in Signal transduction, which is a field of Cell biology. He works mostly in the field of Immunology, limiting it down to topics relating to Apoptosis and, in certain cases, Cell culture.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
ROLES OF THE RAF/MEK/ERK PATHWAY IN CELL GROWTH, MALIGNANT TRANSFORMATION AND DRUG RESISTANCE
James A. McCubrey;Linda S. Steelman;William H. Chappell;Stephen L. Abrams.
Biochimica et Biophysica Acta (2007)
Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy
F Chang;J T Lee;P M Navolanic;L S Steelman.
Leukemia (2003)
Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia
Marina Konopleva;Rooha Contractor;Twee Tsao;Ismael Samudio.
Cancer Cell (2006)
Reactive oxygen species-induced activation of the MAP kinase signaling pathways.
James A. McCubrey;Michelle M. LaHair;Richard A. Franklin.
Antioxidants & Redox Signaling (2006)
Signal transduction mediated by the Ras/Raf/MEK/ERK pathway from cytokine receptors to transcription factors: potential targeting for therapeutic intervention
F Chang;L S Steelman;J T Lee;J G Shelton.
Leukemia (2003)
JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis.
L S Steelman;S C Pohnert;J G Shelton;Richard A Franklin.
Leukemia (2004)
Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance.
James A. McCubrey;Linda S. Steelman;Steven L. Abrams;John T. Lee.
Advances in Enzyme Regulation (2006)
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging
Linda S. Steelman;William H. Chappell;Stephen L. Abrams;C. Ruth Kempf.
Aging (Albany NY) (2011)
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
William H. Chappell;Linda S. Steelman;Jacquelyn M. Long;Ruth C. Kempf.
Oncotarget (2011)
Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway (Review)
Fumin Chang;Linda S. Steelman;John G. Shelton;John T. Lee.
International Journal of Oncology (2003)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
University of Bologna
University of Bologna
East Carolina University
University of Palermo
Sapienza University of Rome
University of Ferrara
The University of Texas MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center
Huntsman Cancer Institute
Korea Brain Research Institute
Los Alamos National Laboratory
Swedish University of Agricultural Sciences
National Institute of Advanced Industrial Science and Technology
University of Strathclyde
Scientific Practical Materials Research Centre
Oregon Health & Science University
Chiba University
University of Birmingham
Tohoku University
University of Victoria
Australian National University
Auburn University
University of Akron
Copenhagen University Hospital
University of Washington
University of Gothenburg